Literature DB >> 15258706

Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.

Isabel Maleno1, Carmen Maria Cabrera, Teresa Cabrera, Laura Paco, Miguel Angel López-Nevot, Antonia Collado, Antonio Ferrón, Federico Garrido.   

Abstract

HLA class I loss or down-regulation is a widespread mechanism used by tumor cells to avoid tumor recognition by cytotoxic T lymphocytes, and thus favor tumor immune escape. Multiple mechanisms are responsible for these HLA class I alterations. In different epithelial tumors, loss of heterozygosity (LOH) at chromosome region 6p21.3, leading to HLA haplotype loss, occurs in 6-50% of all cases depending on the tumor entity. In this paper we report the frequency of LOH at 6p21 in 95 colorectal carcinomas (CRC) previously analyzed for altered HLA class I expression with immunohistological techniques. We used PCR microsatellite amplification of selected STR markers located on Chromosome 6 to identify LOH with DNA from microdissected tumor tissues and the surrounding stroma. Sequence-specific oligonucleotide analysis was performed in microdissected stroma and tumor cells for HLA typing, and to detect HLA haplotype loss. A high frequency (40%) of HLA haplotype loss was found in CRC. Eight tumors showed microsatellite instability. We sometimes observed two or more mechanisms responsible for HLA alteration within the same HLA-altered phenotype, such as LOH and HLA class I total loss. In 25 tumors (26%) no HLA class I alteration could be identified. These data are potentially relevant for CRC patients undergoing T-cell-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258706     DOI: 10.1007/s00251-004-0692-z

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  32 in total

1.  The great escape: is immune evasion required for tumor progression?

Authors:  A Villunger; A Strasser
Journal:  Nat Med       Date:  1999-08       Impact factor: 53.440

Review 2.  MHC antigens and tumor escape from immune surveillance.

Authors:  F Garrido; I Algarra
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

3.  A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

Authors:  M A Morse; Y Deng; D Coleman; S Hull; E Kitrell-Fisher; S Nair; J Schlom; M E Ryback; H K Lyerly
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

Review 4.  Molecular basis for stool-based DNA tests for colorectal cancer: a primer for clinicians.

Authors:  C Richard Boland
Journal:  Rev Gastroenterol Disord       Date:  2002

5.  Criteria to define HLA haplotype loss in human solid tumors.

Authors:  L M Ramal; M Feenstra; A W van der Zwan; A Collado; M A Lopez-Nevot; M Tilanus; F Garrido
Journal:  Tissue Antigens       Date:  2000-05

6.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

Review 7.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

8.  Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas.

Authors:  Isabel Maleno; Miguel Angel Lopez Nevot; Barbara Seliger; Federico Garrido
Journal:  Int J Cancer       Date:  2004-04-20       Impact factor: 7.396

9.  Gene expression in colorectal cancer.

Authors:  Karin Birkenkamp-Demtroder; Lise Lotte Christensen; Sanne Harder Olesen; Casper M Frederiksen; Päivi Laiho; Lauri A Aaltonen; Søren Laurberg; Flemming B Sørensen; Rikke Hagemann; Torben F ØRntoft
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.

Authors:  L A Koopman; W E Corver; A R van der Slik; M J Giphart; G J Fleuren
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

View more
  23 in total

1.  Analysis of HLA-ABC locus-specific transcription in normal tissues.

Authors:  Ana Belén García-Ruano; Rosa Méndez; José María Romero; Teresa Cabrera; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Immunogenetics       Date:  2010-09-15       Impact factor: 2.846

2.  Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.

Authors:  Isabel Maleno; Natalia Aptsiauri; Teresa Cabrera; Aurelia Gallego; Annette Paschen; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2010-11-18       Impact factor: 2.846

3.  LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas.

Authors:  Isabel Maleno; Jose Maria Romero; Teresa Cabrera; Laura Paco; Natalia Aptsiauri; Jose Manuel Cozar; Miguel Tallada; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2006-05-17       Impact factor: 2.846

4.  HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.

Authors:  María A Garrido; Teresa Rodriguez; Svitlana Zinchenko; Isabel Maleno; Francisco Ruiz-Cabello; Ángel Concha; Nicolás Olea; Federico Garrido; Natalia Aptsiauri
Journal:  Immunogenetics       Date:  2018-08-25       Impact factor: 2.846

5.  ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.

Authors:  Claire Y Oh; Martin G Klatt; Christopher Bourne; Tao Dao; Megan M Dacek; Elliott J Brea; Sung Soo Mun; Aaron Y Chang; Tatyana Korontsvit; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2019-09-20       Impact factor: 11.151

Review 6.  Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.

Authors:  Marica Garziera; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 7.  Tumor immunoediting and immunosculpting pathways to cancer progression.

Authors:  Jennifer M Reiman; Maciej Kmieciak; Masoud H Manjili; Keith L Knutson
Journal:  Semin Cancer Biol       Date:  2007-06-26       Impact factor: 15.707

8.  LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.

Authors:  Jacky T Yeung; Ronald L Hamilton; Koji Ohnishi; Maki Ikeura; Douglas M Potter; Marina N Nikiforova; Soldano Ferrone; Regina I Jakacki; Ian F Pollack; Hideho Okada
Journal:  Clin Cancer Res       Date:  2013-02-11       Impact factor: 12.531

9.  Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.

Authors:  Simon Turcotte; Steven C Katz; Jinru Shia; William R Jarnagin; T Peter Kingham; Peter J Allen; Yuman Fong; Michael I D'Angelica; Ronald P DeMatteo
Journal:  Cancer Immunol Res       Date:  2014-02-20       Impact factor: 11.151

Review 10.  Cancer immune escape: MHC expression in primary tumours versus metastases.

Authors:  Federico Garrido; Natalia Aptsiauri
Journal:  Immunology       Date:  2019-10-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.